from the prestigious new england journal of medicine on effectiveness of hydroxychloroquine, the drug touted and taken by president trump in treating covid-19. cnn health reporter jacqueline howard is standing by with results of this study, and so jacqueline, this is not the first time we have heard that this drug is not effective in treating covid patients, but this is the "new england journal of medicine." what do they say? >> now, this study says what other studies have found as well that hydroxychloroquine appears to not provide a benefit to covid-19 patients. now, what this new study, it involved more than 500 patients and hospitals in brazil who were confirmed to have covid-19 and it separated the patients into three groups. some of the patients received standard care n. they did not receive hydroxychloroquine. some patients received hydroxychloroquine, and some received hydroxychloroquine along with an antibiotic wand treated over the course of seven days, and researchers tracked how they were doing up to 15 days. brooke, by day 15, the researchers said they saw no difference i

new concerns tonight about testing in black and hispanic communities in parts of this country. authorities say they are understaffed and have longer wait times. and the new study in "the new england journal of medicine" tonight on antibodies and how quickly they might field after initial infect. abc's victor oquendo leads us off from florida tonight. >> reporter: tonight, with coronavirus in california surpassing new york four months into the pandemic. 60% of cases in los angeles are among young adults. >> in fact, covid-19 appears to be on track to becoming one of the leading causes of death in l.a. county. >> reporter: with the national daily death toll topping 1,000 for the first time in two weeks, more states are now making masks mandatory to try to stop the spread. the governors of ohio, indiana and minnesota joining a growing list of at least 31 states announcing new orders today. >> with this mask mandate and with the things we have done previously to this, i think it is very possible for us to not have the darker days behind us, but for us to start moving forward. >> reporter: president trump refusing to issue a nationwide mask order, holding another coronavirus briefing for the second day i

we've had three studies just published in the new england journal of medicine both as a treatment and as profoe lax sis and shows it increases your risk of heart disease and causes electric disturbances in the heart. this is bad drug for covid-19. the issue is not just the president but the white house will not get their arms around this epidemic and create a national plan and we're descending into chaos. we have 20% of the world's cases of covid-19 in the southern united states. debra birx, dr. birx said the virus is traveling up into tennessee and the midwest and into ohio and indiana and that may reproduce what we have in the southern united states, which is probably the third worst epidemic just the southern u.s., third worst epidemic in globally. we've got teachers who are scared and now threatening to go on strike because they know their being placed in harm's way by being forced to go into schools in the middle of communities where there is lots of raging covid-19. the major league baseball season may be unraveling. nothing is going well and this has become a full fledged homel

the study is published in the new england journal of medicine. >>> a camp running by >>> a lot of school districts have been reaching out to parents for input about the best ways to send kids back to class this fall. >> but what about the teachers? they've just made their concerns clear in a letter to state officials.>> it's scary that going to school and having familiar contact with friends, they don't think they might potentially kill each woied abo comfortable when they had back to campus once again. but for parents like tenniel stewart, there's no other option. going back in person makes the most sense. >> i don't have a great concern at this time that our health is going to be outweighing their safety. >> she says her children's district let her know what new >> some of the tools, hand sanitizer at the door, plastic shields at offices where people walk in. >> all these changes are causing concern for the california teachers association. writing this letter to state leaders think they don't feel safe returning just yet, especially as statistics soar. >> back then it was just starting

yesterday after markets closed moderna released some fresh phase one data published in the new england journal of medicinee giving vaccine developed somei bodies some encouraging news when it comes to the vaccine front t. >> certainly welcome news. >> bill is tracking a major heat wave in the south. and the new streaming service from our parent company that can be yours for free. but we're all going at our own speed. at enterprise, peace-of-mind starts with our complete clean pledge, curbside rentals and low-touch transactions. with so many vehicles of so many kinds, you can count on us to help you get everywhere you want to go... enterprise. you try to stay ahead of the but scrubbing still takes time. now there's powerwash dish spray it's the faster way to clean as you go just spray, wipe and rinse it cleans grease five times faster dawn powerwash. spray, wipe, rinse. could put cookies & creme in twix...twix this is a right twix. excuse me... [screams into pillow] twix cookies & creme.yo c? try new snuggle supercare®.the suy helps neutralize the chlorine in your laundry cycle, helping to keep your clothe

of health released results from their their coronavirus vaccine trial tuesday in the new england journal of medicine. the day to sto 55 all developed antibody after receiving minor flu-like side effects. >> the safety seems to be very, very good. >> reporter: julia is executive director of the center for emerges and neglect diseases at u.c. berkeley, and said that moderna is using new technology. >> moderna is a part of the group that develops rna vaccines, and all out of all of the candidates there, probably the most advanced. >> reporter: the first trials involved mainly white younger adults, and there is still a question about the drug's immunity to covid-19. >> warmer ready to distribute the vaccine when we get it. we're all set. >> we have a lot of work to do to convince people that the science is good, that it's safe and effective. >> dr. art rheingold, a former cdc scientist and u.c. berkeley's school of health said the question of distribution is complicated. >> lit be through primary care physicians, through campaigns on corners? there lit be administered by pharmacist? >> he said what is a

. >> reporter: one of the most promising options was posted just days ago in the "new england journal of medicine." it's described as having the real bullets or neutralizing antibodies in this case to stop the virus. >> that is the cold standard of protection is neutralizing antibodies. it induced it at levels, at a moderate dose of the vaccine that were as high or higher than you see with convalescent plasma after natural infection. >> reporter: this means the closer the vaccine response is to natural infection. >> the vaccine would likely be successful, even though the proof of the pudding is always you have to do the big efficacy trial. >> reporter: while there will be many top contenders, this vaccine is entering a phase three trial testing 30,000 people. there's potential a reliable vaccine could be a reality in a mere six months. dr. fauci says we should have an idea by mid to late fall or early winter how many vaccine candidates are safe and effective to use. stephanie sierra, abc 7 news. >>> abc 7 news has learned governor newsom will order all schools in california to remain closed if th

the results were just published in the "new england journal of medicine." the researchers say that after the second dose, all 45 participants developed neutralizing antibodies, the type needed to fight the virus. according to the study, the antibodies were at levels up to four times the amount found in patients who have recovered from covid-19. >> our vaccine generates neutralizing antibodies to levels that seem to be higher than what you get with a typical infection. that's important because even if immunity wanes over time, the higher you start, the longer the runway technology it wanes. >> reporter: but dr. anthony fauci tempered expectations. >> no vaccine is going to be 100% protective. what we hope is that with a combination of people having already been exposed and a vaccine that's anywhere from 70, 75% effective that there will be enough herd immunity that there will be a time when you and i don't have to worry about getting infected with this awful virus. >> for now, moderna is aiming to enroll 30,000 adults in its phase three trials, set to begin

what we have shown in the human study that was published in the new england journal of medicine, it hash factor of neutralizing antibodies, four times more than people and have been -- people that have been naturally infected. everybody else, every other company, we have to run the phase three. vaccines seeing other producing a t cell response. is this going to be one of the key differentiators, you think, as to whether or not we get an antibody and cellular response? is that going to be one of the areas we are -- people are going to receive it? stephane: people are actively looking to differentiation right now because we don't have any more data. not only from industry, but the regulators, what do we know today? from the phase one study published data. the real test everybody is going to have to go through is 30,000 plus ofants, 50% control. -- theng the number of phase three is going to be the real test for everybody. nejra: that was stephane bancel. just want to bring you read headline. this is according to bloomberg reporting. nissan is not planning to pay a dividend for the current

also a lot of evolving science on this i mean i read some of the early papers in the new england journal of medicine about this and i'm really not qualified to judge even though i have some scientific background i definitely have no medical background and i think the scientists have been all over the map on this so i disagree with those who say that found she is motivated by that intentions and i think there are some people saying that i don't there's any evidence of that i think he's done the best he can when he's been right has been right when he's been wrong he's been wrong i think his intentions have been good but he approaches the problem differently say then peter to borrow who say who's an economist who's not a doctor who looks at the economic cost of the shutdowns and i think the point is that there's tradeoffs there are always tradeoffs the economist wants people who go back to work and the doctor wants people to stay home and somewhere you know in the middle somewhere in the middle of that there's there's where the public is going to find itself yeah what is an economists know about spread

tucker, this week to big studies came out, one out of brazil that was published in "the new england journal of medicine the gold standard, double-blind, and another study in the annals of internal medicine. both of them show that hydroxychloroquine does not seem to work early in hospitalization or before patients go in. that's where the scientists right now. more studies need to, and i think it is not the right time for anecdotal evidence for doctors to get there in that white coat ceremony's and to shake and rattle and say, take it, take it, our patients got better. that's a month or so ago and now we are on to scientific studies. does that mean we don't have a right to do it? no. that's free speech and they have every right to express their medical opinion and facebook should be ashamed. the video should be posted. me, follow the science. >> tucker: thank you, dr. siegel, for that. i don't see any evidence, and that's another thing they said in the video and that was pulled off of the internet. is there any justification for that statement? >> young children are much less likely to spread this and th

early data in the number one journal in britain with over 30 authors and published in the new england journal of medicinewhich is our holy grail of journals and done very transparently. there is transparency, top scientists involved, we are seeing every step of the way how this is going. is going fast but we are aware of it, the president was very forthcoming about this. i expect this to be a bipartisan situation. shannon: especially benefiting people across the country hopefully around the world with what is coming together. i want to ask, the debate continues about what we learn and discover about this virus, some new jersey gym owners we covered live, they stayed open, put in temperature checks, distancing at all kinds of things but the state told them you cannot be open, they were arrested today, one was on earlier and said i'm not upset about being arrested, that is what i have to do to feed my family. here's what he said. >> i'm not afraid of tyrants, no american should be because we outnumber them greatly and the only thing they run off of his fear which is why you see what you see in the media wh

one out of brazil that was published in "the new england journal of medicine," the gold standard, doublelinded prospective randomized trial of her 600 patients, another study, we've been following the minnesota study. both of them show that hydroxychloroquine does not seem to work early and hospitalization or before patients go in. that's where the sciences right now. more studies need to come. i think it is not the right time for anecdotal evidence for doctors to get there in white coastge ceremonies and say take it, take it, our patients got better, our patients got better. that's a month or two ago. now we're onto the scientific studies. does it mean they don't have a right to do it? no, this is free speech. they have every right to do it and have every right to express the medical opinion and facebook should be ashamed. the video should be posted, follow the science. the science right now is not, this week, behind hydroxychloroquine, tucker. >> tucker: thank you, dr. siegel, for that. really apprised from day want to stick to that standard. very quickly, i don't see any evidence -- h

what we have shown in the human study that was published in the new england journal of medicine it hashigh ability to neutralize muchodies, four times as as people who are naturally infected, and t cells, which is a very good sign. for full efficacy over vaccine. vaccinesave seen other have a t cell response. is this going to be one of the key differentiators as to whether or not we get an antibody and a cellular response? is that going to be one of the areas that people are going to receive it, where they need to differentiate? think people are actively looking to those differentiations now because we don't have more data. so everybody is trying from regulators, to look at what do we know today, from the phase one study and published data. but the real test that everybody is going to have to go through participants study, 50% plus on getting the knowing the really efficacy of the vaccine. be the real test for everybody. moderna chief was bancel.e stephane investors may seek out more bullish signals before pushing prices higher. we will discuss prospects for the precious metal next. th

a new study led by researchers in brazil show the use of a controversial ma kwlarn drug does not help covid-19 patients. according to the study published in the new england journal of medicine, hydroxychloroquine did not improve hospitalized patients with mild to moderate covid-19. shasta darlington, cnn, san palo. >>> the country has the fourth highest death toll in the world. matt rivers is in tijuana with more of the strain on the resources there. >> reporter: yet another record day here in mexico with health officials thursday evening reporting more than 8400 newly confirmed cases of the virus. that is the largest day-to-day increase since the virus began. we know the effects have been felt severely in border communities like this one. we're in the mexican state of baja, california. it sits west of the united states. the effects of those early cases are still being felt right now. consider the mortality rate. roughly 20% of all people that have contracted the virus have died as a result. that's one of the highest mortality rates of all of mexico and mexico has one of the highest mortality rates of any country worldwide. we've spoken to doctors that have totals that hosp

some of them got it early and the new england study -- >> that was a pure -- the new england journal of medicine study came out, the median time for them to get the medicine the first time they got it was seven days. that's about five days too late. >> we don't need to go down this road anymore. dr. anthony fauci -- i have spoken to dr. o'neill at length. the doctor who wrote the report in the study says it doesn't disprove the other studies which have talked about the limitations. >> -- been on your show? >> no, peter. >> they're better spokesman than i am. >> why doesn't the president talk about them instead of stella emanuel? >> he mentioned them. as soon as you go there, this is a circus again. i'm trying to have a serious discussion. >> but people -- >> people of cnn and you want -- >> the president wants circus. the president wants circus. the president wants circus. the president wants circus. why not -- >> this week we demonstrated the use of the defense production act can get a vaccine to the american people in half or a third of the time. we did a beautiful job on tuesday with the grea

of not trusting public health figures is not totally new. i remember when i was covering ebola back in 2014 there was some of this. there was an article in "the new england journal of medicine" about what the trust levels were in public health officials and about a third of the country said it was very high. probably more than it is now overall, by not spectacular numbers even back then. i think what really strikes me about this is that eventually all these states and these communities are going to have to do the thing that needs to be done in terms of trying to curve the transmission of this virus. i think what dr. fauci and others sbrn trying to say is look, this is a less painful way to get there if you follow these guidelines and these evidence-based recommendations. we're trying to give you the power to make these decisions because ultimately the virus will make the decision for people. the hospitals will become too full. they won't be able to take care of patients and the decisions will become obvious at that point of what needs to be done. so, in the end, the same outcome is going to happen. it's just going to be a lot more painful, i think, if people aren't listenin

what we have shown in the human study that was published in the new england journal of medicine thateeks ago is neutralizing antibodies around four time -- people that have been naturally infected, and we have also shown t cells, which is a good sign for the consumer vaccine. phase three.n the guy: we are seeing other vaccines producing a t cell response. is this going to be one of the key differentiators you think as to whether or not we get an antibody and a cellular response. is that going to be one of the areas people will receive it need to differentiate? people are actively looking to the differentiation now because we do not have any more data. , thebody is trying industry, the regulators, to map out what we know from the phase , and are only a few -- the real test everyone will have to go through is to run 30,000 participants of phase three study, placebo-controlled, every other person getting the vaccine and every other person getting a placebo. people have to guess whether phase three will be the real test. alix: how do you price the vaccine? guy: we have not communicate -- ste

find out what the results of a vaccine trial are, they're going to hear about it in the new england journal of medicinenyway. lou: do you think somebody should tell him about the fact that two chinese nationals have been arrested for spying on the firm that he advises, moderna, and the other biotechs trying to create a vaccine? i guess he missed that part. leading radical dem dianne feinstein, like her party, embraces communist china. she says china is a respectable nation despite its refusal to warn the united states on the the china virus that originated in china and killed more than 150,000 americans without their warning. >> we hold china as a potential trading partner, as a country that has pulled millions of -- tens of millions of people out of poverty in a short period of time and as a country i growing into a respectable nation among other nations. and i deeply believe that. lou: and she is deeply preposterous. americans overwhelmingly condemn the chinese communist government, and they blame them for spreading the china virus. a pew poll finds 78% of americans say china is responsible for sprea

those results were published in the new england journal of medicine. the company's chief medical officer spoke with cnn about what happens next. >> we believe that the chances of this working are pretty good and the reasons are that the neutralizing antibodies i think has been demonstrated for other similar viruses and in clinical models. we've shown levels can exceed what you see with natural infection and so on balance we're cautiously optimistic but fully dedicated to seeing this through. >> joining me now is dr. mark sapino, emergency medical system at jackson health system in florida. thank you for being with us and for all that you do. >> thanks for having me. >> so intensive care units in 54 florida hospitals are full. the whole of miami-dade county has run out of icu beds. 26 patients will now have to be moved to converted icus and vent lator use is up 92%. it is a covid hot spot. and you're working on the front line there in miami. what is happening at your hospital? what are you seeing? >> we are full. i don't have many other words to describ

the results were published online in the new england journal of medicine and showed that the signs wereand well tolerated. dr. anthony fauci called it good news saying, quote, the gold standard of protection against a viral infection is neutralizing antibodies. and the data from the study small numbers as it may be are pretty clear that this vaccine is capable of inducing quite good levels of neutralizing antibodies. the next stage, 30,000 adults, half receiving the vaccine, half placebos. many will be in hot spots such as texas, florida, arizona. this decision will likely help gather the efficacy of the vaccine sooner because more people will be regularly exposed to the virus. moderna plans to run the study through october of 2022. but preliminary results are expected well before then. with that, let's get a chk-in with nbc meteorologist bill karins. i know you're going to be but that is smd good neis some the vaccine front as we've been awaiting something to come out, hoping that it does emerge on the markets early on next year. >> yeah, we're also desperate for good news, yasmin, to

the nih vaccine working group wrote in the "new england journal of medicine" they say currently we lackcient knowledge of coronavirus pathogenesis to inform inclusion and exclusion criteria for a challenge trial. a single death or severe illness in an otherwise healthy volunteer would be unconscionable and would halt progress. how do you get over the moral hurdle here because in any situation, that possibility would exist. >> i think there's a grain of truth in what's said there in that we do not know all the answers. we cannot tell someone there's a 0.01% chance or some precise number that anything bad will happen to you or even a precise number for their risk of dying. what we can do is we can give them -- we can select volunteer who is first are at the lowest possible risk because of their age and health conditions, lack of other health conditions, and we can have a serious discussion with potential volunteers. 30,000 plus people have said they would like to do this. of those, when they understand what they're offering to do, some will say, no, i didn't realize, and those people will

this was actually pretrade best by the editors a few years ago of "the new england journal of medicine,"d the landsat and the medical journal association who complained they were feeling under pressure by drug companies to run multiple studies through those journals to format the studies in such a way that they would get through peer review easily and swamped the major medical journals. and they felt that this was the pressure on the journals and them to carry out this policy. and i think this drug company pressure has been dated a large amount of the medical establishment so it's hard to get independent work and independent reviews done today and i think some of the pressure came from the admission only and the media picked up on it, seeing an opportunity to slap the message way that the media want to slap. >> sean: doctor, do you believe dr. wallace from cedars-sinai, thatat the risk is nil, do you agree with him? a65-year-old drug? i'm not a doctor. you are. what are your thoughts? >> yes. this drug is been taken more than a billion times. it's exceedingly safe. a group of cardiolog

talked about this before, but in this particular case, it was peer review and in the "new england journal of medicinehat's your take where moderna is and where we are in terms of the vaccine race? >> it's a small but important first step. i mean, you have basically 45 people who were tested. divided into three groups. one of the groups received the dose that will be the final dose and therefore tested in 15 people. have been shown to have, you know, a kind of immune response, neutralizing antibody response at least compares favorably to the kind of neutralizing antibodies you see after people are naturally infected. that's all good, but, again, it's 15 people who got the dose that will be the final dose. take a step back and tell you what worries me most about this. this is a bad coronavirus that just made its debut in the human population and already has caused a series of clinical syndromes one would have never imagined. this was a winter respiratory virus raging in summer months, raging in hot and humid climates. causing an unusual multiorgan multisystem disease in children. it can affect our abil

immune responses in all who volunteered to take it according to those published in the new england journal of medicine, a fully vetted and readily available vaccine is still a good ways off. the coronavirus task force meets today in private and with the soaring summer case count come new warnings about whether it's safe to reopen schools and new debates about the only way to stop the spread now is to roll back some of the economic reopening. the moment is urgent. the issue is quite complicated and very consequential and from the president another simplistic and not to mention, a ridiculous attempt to explain it all away. >> frankly, if we didn't test you wouldn't have all of the headlines. think of this, if we didn't do testing instead of testing over 40 million people, if we did half the testing we'd have half the cases. if we did another -- you cut that in half we'd have yet again half of that, but the headlines are always testing. >> the headline the president says is always testing. that's not the only headline, but the testing is critical because it gives us the numbers that feed this map and thi

>> we were looking at that but the cdc, the w.h.o., even an article in this new england journal of medicine still disputed where masks are effective. >> the leaches are still used in medication in some applications. there's research on that. i won't start on cocaine and heroin. that seemed like a weird comparison. >> my interception was that data's constantly changing, evolving. it's not that dr. fauchi was necessarily wrong. he was going by the data or the lack thereof. i want to go back to segment you were showing earlier. if i may set the record straight here. dr. fauchi is a gentleman who has devoted his life and his career to the health and well-being of the american people. he has just -- he is so well-respected around the world. think about it this way, joshua. you or any of our viewers had a very about thyroid or lupus medications, do they call their mayor, their representative or do they call a doctor? we should be listening to the career scientists and doctors like dr. anthony fauchi. >> we know that president trump and dr. fauchi have not seen eye to eye. you don't fight with som

this data coming out in the new england journal of medicine. appears that moderna in the lead with its vaccine candidate, producing antibodies in all 45 of the patients tested. i mentioned we are standing by for president trump. the press conference scheduled to start any moment now. we are told that the south china sea and ongoing relations with china will be the focus along with potentially rising cases of covid-19 across the country. meantime, taking a look at how this impacted the markets. volatility again the word of the day. i want to bring in abigail doolittle, who has been following all of this. abigail: volatility is certainly the word of the day and really the word of the last month. the s&p 500 yesterday unable to take out its high after the february-march crash. so that resistance kicking in, that choppiness, uncertain the on the part of investors. aat news from modano could be game changer tomorrow. but today, at the end of the day, we had stocks higher, but that is not the way we started. investors working through, just trying to

institute of health released results from the coronavirus vaccine trial, tuesday in the new england journal of medicinehe data shows 22 men and 23 women, ages 18 to 55 all developed antibodies after receiving two doses of the vaccine candidate. most with only minor flulike side effects. >> the safety seems to be very good. >> reporter: julius alaska is executive director of the center for emerging and neglect diseases at uc berkeley. she says moderna is using new technology. >> the dharna is the group that develops rna vaccines. all of the all the candidates, there probably the most advance. >> reporter: the first trials involved white, younger adults and questions are made about the vaccine's safety and whether it provides immunity to covid-19. on july 27th, moderna will begin phase three with 30,000 people. >> we are ready to distribute the vaccine when we get it. we are all set. taking a risk, and economic risk of preparing for delivery because we feel very certain it's going to be there. >> even once we have this vaccine, we have a lot of work to do to convince people that the science is good, that

early data, the number one journal in britain with over 30 authors and published in "the new england journal of medicineholy grail of journals and it showed its data very transparently. so this transparency, there's top scientists involved, we are seeing every step of the way how this is going and it's going fast, but we are aware of it. the president i spoke to last week and he was very forthcoming about this. i expect this to be a bipartisan situation. >> shannon: especially if it's going to benefit people across the country, hopefully around the world with what's coming together. i want to ask you though because this debate continues about what we learn and discover about this virus as we go. there are a couple of new jersey gym owners that we have covered a lot, they have stayed open, they put in temperature checks all kinds of things but the state has told them you cannot be open. they were arrested today. one of them was on earlier he said i'm not upset about being arrested, i'm just sorry that this is what i have to do to feed my family. here's a little bit more of what he said. >> i'm not afraid

news from moderna. the stock is up in the after hours session. meg? >> this is the phase one study of moderna's covid-19 vaccine program. the full results being published in the "new england journal of medicine" this medicine." the study showed that the neutralizing antibodies the vaccine generated in all participants and the dose level at 100 micrograms, they found these neutralizing levels were about two to four times higher than what you see in people who have recovered from the disease. neutral asizing antibodies block the virus from being able to infect cells pfizer saw about two to three times higher neutralizing antibody levels. we spoke with moderna's chief medical officer. he said the results are similar between the two vaccines and he was encouraged by the pfizer data and the moderna data. of course the question is going to become how long does this protection last. and we just don't know that. these results were as of day 57, so they are going to start a phase 3 trial on july 27th of 30,000 participants and that will give us the answer about how protective this looks to be now. >> meg, these are the full results of a study that had been sort of i don't want to say alluded to but s

according to the results published in the "new england journal of medicine," the participants showed ibodies than some patients who have recovered from the virus. that's huge. now moderna was the first company in the united states to begin testing coronavirus vaccines in humans. and now will be the first in the u.s. to move to phase iii trials, which includes 30,000 participa participants. so it's a real exponential growth in the number of people being tested with this vaccine. joining me now, dr. evan anderson with emory university and one of the principle investigators on this study. it's good to have you, dr. anderson. so, first, help the viewer here. phase iii, we know, 30,000. so phase iii trials would end in late october. then what? >> yeah, so the phase iii enrollment will be over a couple month time period, which roughly puts us to the end of september into october. but we then follow participants out for two years to evaluate whether or not they acquire coronavirus in the midst of their daily lives. >> so what have we learned so far about this virus? two things, one, what did

the results of their phase one trial published in the new england journal of medicine. it is a small sample, but it does show all 45 people who participated in receiving the vaccine produced antibodies against the virus. that vaccine is expected to begin a larger phase three trial at the end of the month, some 30,000 people take part. two potential vaccines from u.s. pharmaceutical company pfizer have also been newly fast-tracked by the fda. trials underway as well for a vaccine from johnson & johnson as well as astrazeneca and novavax. all of those firms working at warp speed to get a vaccine to the american people as quickly as possible. the dow jones industrials reflecting investor approval, climbing 228 points. the s&p 500 up 29, the nasdaq rising 62 points. as for the pandemic itself, the number of cases in this country has been rising in 41 states as well as washington d.c. those cases have fallen or remain flat in nine other states. overall, the death rate is actually declining as testing and cases continue to increase. over the past two months, cases have risen

it was published in "the new england journal of medicine," which is highly respected. the stock market 28 points this morning. since, it has come back a little bit. but what happens now? moderna gives this trial. even dr. anthony fauci is cautiously optimistic. >> i think we are in a pretty good place when it comes to vaccines. i mean, obviously, you want to prove that it is safe and effective, but if things work out the way that we hope they do, i think by the end of this year and the beginning of calendar year 2021, we will have enough information to know whether the candidates that we are dealing with are safe and effective. >> starting phase three trials now, it bodes very well for having that vaccine by the end of the year. we already know that yesterday, companies are buying the production materials that they need to manufacture this vaccine. a senior meant administration official said four to six weeks from now, we can have manufacturing started even before it is approved by the f fda. >> dana: all right. edward lorenz number thank you. a question of when and ho

the results of their phase one trial published in the new england journal of medicine.all 45 people who participated in receiving the vaccine produced antibodies against the virus.

only last a few months and people who have mild illnesses new research published in the new england journal of medicine suggests that about half of the antibodies are gone after roughly 10 weeks. however, scientists say this does not mean all protection is gone or that it will be possible to develop an effective vaccine until there is a coronavirus vaccine, anybody therapies could be the bridge to treating covid-19. >>that involves taking antibodies from the blood of someone who has already been infected and recovered to get those antibodies seen each remove plasma from the patient. within the plasma they're likely to find antibodies which specifically attached to this part of the virus, it's called the spike protein and it is the key to entering human cells. >>if an antibody binds this little finger part. that's obviously going to block the attachment to the cell. that will neutralize the virus and a body or the plasma from countless patients allows you to. accomplished at least temporarily what we're trying to accomplish with the back saying. you can just give me an abiding call s even union station

results released in the new england journal of medicine. 22 men and women received antibodies most with only flu like side effects. >> the safety seems to be very good. >> julia is executive director of the center for emerging and neglected diseases at uc berkley and she says they are using new technology. >> ma der na is a part of the group that develops vaccines and out of the candidates they're probably the most advanced. >> the first trials involved white younger adults and questions remained about the vaccine's safety and whether it provides immunity to covid-19. on july 27th ma der na will begin phase three with 30,000 people. >> we're ready to distribute the vaccine taking an economic risk to prepare. >> once we have this vaccine we have a lot of work to do. to convince people that the science is good. that it's safe and effective. >> dr. art rhine gold the former cdc scientist and professor of escape domoologist says that question of distribution is complicated. >> through primary care fission physicians or campaigns on corners? will it be administered by pharmacists. >> dr. rhi

it's at $82.41 right now, still a gain of 9.7% after the new england journal of medicine said the company's early stage human trials of its coronavirus vaccine candidate triggered neutralizing antibodies in all the test patients. now, while the vaccine was generally well tolerated, we do have to tell you that more than half of the participants reported adverse side effects from everything regarding muscle aches to fever and chills. but either way, the news really giving a boost to sectors that had gotten trounced in the spring as states lock down and americans stay at home. cruise lines, look at this. carnival, royal caribbean, norwegian, all jumping, big move for norwegian up 18%. even bigger for royal caribbean, up 20%. carnival bringing up the rear at 14.7%. >>> a mere whiff of a vaccine has been a godsend to investors who stuck it out with the airlines. it's been a rough ride here. but it's sailing high right now. we have american, delta and united seeing decent gains here. ual is up 14.5%. american up 14.8%. delta moving higher by 9.25%. fwle let's flip it to the hotels. marriott inter

the study just released by the new england journal of medicine says a vaccine developed by the drugmakerna induced immune responses and everyone taking part in its trial with no identifiable safety concerns. moderna says it expects to start the next phase study of the vaccine on july 27th involving some 30,000 adults

reason why, chief medical officer at mo dederna and the candidate has come out in the new england journal of medicineanks for being with us. can you walk through what the latest trial found and what you expected? >> good evening, anderson. this is the first trial our colleagues actually have tested the ability of our vaccine to generate an immune response in healthy volunteers. what was done here is to expose three groups of individuals to low, medium and high dose and measure in the glad how much antibodies do they produce and whether those antibodies could indeed inhibit the ability of this virus to infect cells. of course, the first thing you look for is always safety and to tolorabilty. every individual exposed, even at the lower dose, we can see antibodies and have a new trelizitrel i -- neutralizing activity. the levels of the antibodies exceed on average the levels of antibodies you see in people that have been sick with covid-19. on the other side, the safety and profile is what you would expect consistent with what we've seen with other similar vaccines with our technology and so the good ne

and even in may there was a new england journal of medicine article that disputing whether or not masks were effective. >> reporter: and even as icu and morgues are filling and cases continue skyrocket, adams and other task force officials today are insisting the situation hasn't spiralled out of control and we're in a better place than in march and april because we have more testing, better treatments like remdesivir as well as a clear understanding of precautions like masks and social distancing giving the u.s. a better fighting chance and adams pointing out that since it takes about two to three weeks for coronavirus to run its course through the body and stop being contagious, if you wear the masks, he argues this could be turned around regularively quickly. >> we'll see if that will happen. thank you so much from the white house. >>> a new poll and perhaps a another stunning blow to the trump campaign and the secretary of education on whether president trump's threat to pull funds from schools that do not open is real. that's next. and more one of a kind finds. it all ships free. a

>> it's an interesting study out of the "new england journal of medicine" and from italy and spain. corroborates a study that was previously done in china saying that if you of a "o" type, you might be less -- have less severe disease, whereas if you have "a" type, you might have a little more severe disease. i think at this point there needs much more research. we obviously know that genetics matter in how our bodies get impacted by disease. and this might be a consideration, but there definitely needs to be more study in order to get really definitive conclusions. >> our station in los angeles has talked to one of california's first coronavirus patients. he says doctors have told him his antibodies have already begun diminishing. what do we know, and is it possible to eventually lose one's immunity to this virus? >> the question really is surrounding immunity. do we have immunity after getting covid? and if we do, then to what degree? for instance, if we have had covid, then if we get it again, are our symptoms far less than we would have if we hadn't had it before? if we do have i